ReviewCNS neuroscience & therapeutics2026
The Roles of EETs in Neurological Disorders.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEpoxyeicosatrienoic acids (EETs) are bioactive lipid mediators derived from arachidonic acid (ARA) via cytochrome P450 (CYP450) enzymes. They exert pleiotropic effects including anti-inflammation, anti-apoptosis, antioxidant activity, and vasodilation. Soluble epoxide hydrolase (sEH) rapidly hydrolyzes EETs to inactive diols, and its inhibition has emerged as a promising strategy to potentiate EET-mediated benefits. This review synthesizes current evidence on the roles and mechanisms of EETs and sEH in major neurological disorders and discusses translational challenges and future directions.
methodsA narrative review was conducted to synthesize evidence on the biosynthesis and metabolism of EETs, the expression and regulation of brain cytochrome P450 epoxygenases and sEH, the neuroprotective effects of EETs, and the therapeutic potential of sEH inhibitors, and to identify current limitations and future strategies for sEH-targeted therapies.
resultsEETs ameliorate multiple neurological disorders through anti-inflammatory and anti-apoptotic effects, increased cerebral blood flow, reduced excitotoxicity, decreased dendritic spine loss, reduced oxidative stress, and enhanced neurosteroid secretion. In animal models, sEH inhibition elevates endogenous EET bioavailability, slows progression of various central nervous system diseases, and attenuates brain injury. However, sEH inhibitor development faces several challenges, including species differences in CYP expression, insufficient blood-brain barrier penetration, bleeding risks, failure of some candidates in late-stage trials, and the limitations of single-target inhibition.
conclusionsEETs are endogenous multifaceted neuroprotective mediators that act through convergent anti-inflammatory, anti-apoptotic, and vascular mechanisms. sEH inhibition represents a highly attractive yet challenging therapeutic strategy for a wide spectrum of central nervous system disorders. Future progress requires: development of brain-penetrant or dual-target sEH inhibitors; identification of EET-specific G protein-coupled receptors (GPCRs) and biomarkers for patient stratification; improved preclinical models that better translate to humans; and rigorous clinical evaluation to define safety and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.